Treats insomnia characterized. ANDA 202337, held by Rk Pharma. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 202337 (Doxepin Hydrochloride), held by Rk Pharma, was first approved by FDA on Jan 20, 2016, with 1 approved supplement and 0 published complete response letters.
Doxepin tablets are indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 20, 2016 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 3MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 6MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
| Nov 12, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 20, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters